15 October 2020 
EMA/CHMP/544469/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Lacosamide UCB 
lacosamide 
On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Lacosamide UCB. The marketing authorisation holder for this medicinal product is UCB Pharma S.A. 
The CHMP adopted a new indication for the use of Lacosamide UCB as adjunctive therapy in the 
treatment of primary generalised tonic-clonic seizures in patients from 4 years of age with idiopathic 
generalised epilepsy. 
For information, the full indications for Lacosamide UCB will be as follows:2 
Lacosamide UCB is indicated as monotherapy in the treatment of partial-onset seizures with or 
without secondary generalisation in adults, adolescents and children from 4 years of age with 
epilepsy. 
Lacosamide UCB is indicated as adjunctive therapy 
- 
- 
in the treatment of partial-onset seizures with or without secondary generalisation in adults, 
adolescents and children from 4 years of age with epilepsy. 
in the treatment of primary generalised tonic-clonic seizures in adults, adolescents 
and children from 4 years of age with idiopathic generalised epilepsy. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
  
 
 
 
